Bydureon BCise Dosage

Generic name: EXENATIDE 2mg in 0.85mL
Dosage form: injection, suspension, extended release
Drug class: GLP-1 Agonists (Incretin Mimetics)

Medically reviewed by Drugs.com. Last updated on Nov 1, 2024.

•: The recommended dosage of BYDUREON BCISE is 2 mg subcutaneously once every 7 days (weekly). The dose can be administered at any time of day, with or without meals.
•: Discontinue an immediate- or extended-release exenatide product prior to initiation of BYDUREON BCISE. Patients changing from another extended-release exenatide product to BYDUREON BCISE may do so at the next regularly scheduled dose. Patients changing from immediate-release exenatide to BYDUREON BCISE may experience transient (approximately 2 to 4 weeks) elevations in blood glucose concentrations.
•: The day of weekly administration can be changed if necessary, as long as the last dose was administered 3 or more days before the new day of administration.

Recommendations Regarding Missed Dose

•: If a dose is missed, administer the dose as soon as noticed, provided the next regularly scheduled dose is due at least 3 days later. Thereafter, administer subsequent doses once every 7 days (weekly).
•: If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, do not administer the missed dose and instead resume BYDUREON BCISE with the next regularly scheduled dose.

•: Prior to initiation, train patients and caregivers on proper mixing and injection. Instruct caregivers to assist pediatric patients with mixing and administration.
•: Remove the autoinjector from the refrigerator 15 minutes prior to mixing the injection, in order to reach room temperature.
•: Mix by shaking vigorously for at least 15 seconds.
•: Inspect BYDUREON BCISE visually before use. After mixing, BYDUREON BCISE should appear as an opaque, cloudy, white to off-white suspension, evenly mixed with no residual medicine along the side, bottom or top of the inspection window. Do not use if particulate matter is present or if discoloration is observed.
•: Administer BYDUREON BCISE immediately after the autoinjector is prepared as a subcutaneous injection in the abdomen, thigh, or upper arm region. Advise patients to use a different injection site each week when injecting in the same region.